Broadcom’s AI Sales Surge: The Binary Gauge for Tech Spending

The setup is clear. AI spending is the engine, but inflation is the headwind. Here's the watchlist to ride the signal and hedge the noise.

The Pick: Broadcom (AVGO) – The AI Spending Barometer This isn't a stock pick; it's a market signal. When AVGO prints, the AI infrastructure story gets a reality check. Last quarter, its AI ASIC sales more than doubled, driving 29% revenue growth and a staggering 68% adjusted EBITDA margin. That's the kind of profit power that makes it a bellwether. Analysts see more upside, with an average price target implying a 38% gain from here. Watch its guidance for the next quarter-it's the canary in the coal mine for tech capex.

The Play: Vivos Therapeutics (VVOS) – The Resale Registration Watch This is a high-risk, high-reward registration play. Vivos just secured $850,000 in cash via a dilutive private placement (PIPE) with attached warrants. The deal concentrates control, with one investor now holding 19.9% of outstanding shares. The critical path is the resale registration statement it must file within 45 days. If the SEC clears it, the warrants (exercisable at $1.09) could flood the market, adding massive dilution risk. This is a binary event-watch for the filing date and the subsequent stock action.

The Hedge: Defensive Stocks for Inflation Resilience With inflation data due this week, the focus shifts to companies that can pass costs through. While not a specific pick here, the thesis is to identify businesses with pricing power and sticky demand. They're the anchors when the AI trade gets choppy.

The Defensive Watchlist: 3 Specific Picks for Monday

When the AI trade gets choppy, you want anchors. Here are three specific, low-volatility stocks from the evidence to offer stability amid uncertainty.

First, the clear defensive staples: Medtronic PLC (MDT) and Church & Dwight (CHD). Both are highlighted for stability in a list of low-volatility picks. They operate in essential sectors-healthcare and consumer staples-where demand is sticky even when the economy wobbles. That's the definition of a defensive play.

Then, there's an undervalued gem: Sotera Health. It's trading at a 25% discount to its estimated fair value based on future cash flows. That's a classic value setup. The company provides critical sterilization and lab testing services for the healthcare industry, giving it a resilient business model. The discount suggests the market is overlooking its strong earnings growth potential.

Finally, for a tech-adjacent defensive bet, look at JPMorgan's top picks. The bank added JFrog (JFRO) and Palo Alto Networks (PANW) to its list in April, seeing them as AI adoption beneficiaries. While not pure defensive, their focus on software infrastructure gives them a more stable, recurring revenue profile than pure growth stocks. They're the tech equivalents of a utility.

The bottom line: This watchlist blends proven stability (MDT, CHD), a deep-value opportunity (SOTER), and a tech-adjacent, cash-flow-focused pick (JFRO, PANW). It's a balanced hedge for a volatile week.

Catalysts & What to Watch

The theses are set. Now, here's what to monitor to see if they hold or break.

For AVGO: The AI Spending Barometer The setup is clear. Broadcom's growth is a direct read on the health of the AI capex cycle. The near-term catalyst is Alphabet, Meta, Amazon, Microsoft, and others spending $650 billion on capital expenditures this year. Watch for any commitment from these giants to cut back or delay spending. The company's own guidance is the canary. It expects AI semiconductor sales to be $10.7 billion in the second quarter. If that number gets cut, it signals a slowdown in the data center build-out. Conversely, any upward revision would confirm the acceleration thesis. The stock's 38% upside target hinges on that spending staying robust.

For VVOS: The Binary Registration Event This is a pure event-driven play. The critical path is the resale registration statement. The company $850,000 in cash and converted debt, but the real risk is the warrant overhang. Watch for the filing date (within 45 days of March 31) and, more importantly, the subsequent stock action. If the SEC clears the registration, the large holder (now with a 19.9% stake) could start selling shares. Any significant share sales or a delay in the registration process would be a major red flag. The warrants, exercisable at $1.09, create a potential flood of new shares, so monitor trading volume and price pressure closely.

For the Defensive Watchlist: Inflation & Earnings Resilience The hedge thesis depends on two things: inflation data and corporate earnings. This week, the key data is the Consumer Price Index report for March and the Personal Consumption Expenditures data. If inflation cools more than expected, it could pressure the case for defensive stocks that rely on pricing power. If it stays sticky, it validates the thesis. Then, watch the earnings reports for the defensive picks. Look for signs of double-digit earnings growth and management commentary on cost pass-through. For Medtronic and Church & Dwight, consistent results in their core markets will prove their stability. For JFrog and Palo Alto Networks, evidence of resilient software demand and strong cash flow will show they are true tech utilities, not growth stocks vulnerable to a rate hike.

The AI Engine: Broadcom's Binary Bet

This is the core thesis. Broadcom isn't just riding the AI wave; it's the engine. The stock's performance is now binary: it needs sustained, massive spending from Meta and Alphabet to justify its premium. The setup is clear, and the metrics are staggering.

First, the dominance. Broadcom holds an estimated 60% of the AI application-specific integrated circuits market by 2027. That's a fortress position. The proof is in the numbers: its AI revenue jumped 106% year-over-year to $8.4 billion last quarter. That's the kind of acceleration that drives a 449% stock run over three years.

The forward view is even more aggressive. The company expects AI semiconductor sales to be $10.7 billion in the second quarter. That's the canary in the coal mine for the entire data center build-out. The stock's 38% upside target hinges entirely on that number holding or rising.

Then there's the signal from management. A new $10 billion share repurchase program is a massive vote of confidence. They're telling shareholders they see a path to that $463 price target and are willing to buy back stock at a ~38% discount to that level. It's a powerful alignment of interest.

The bottom line is binary. The AI spending engine is real, with Alphabet, Meta, Amazon, Microsoft, and others committing $650 billion to capex this year. But if that spending slows, Broadcom's 68% adjusted EBITDA margins and 47% revenue growth guidance for the next quarter could quickly unravel. For now, the engine is roaring. Watch the guidance, and watch the giants' spending announcements.

The Biotech Speculative Play: Vivos Therapeutics

This is a pure high-risk, high-reward bet. Vivos just raised a tiny $850,000 via a dilutive private placement, but the real story is the concentrated ownership and the warrant overhang that could flood the market. It's a classic speculative setup.

The numbers tell the story. The company secured $850,000 in cash and converted $1.4 million in debt into equity-linked securities. That's a lifeline, but it came at a steep price. The deal issued warrants that could dilute shares at just $1.09 per share. That's a massive overhang-up to 3.9 million new shares could be created if all warrants are exercised.

Then there's the ownership shift. A single investor group, SP Manager LLC, now controls 19.9% of outstanding shares. That's a huge concentration of power. The company's own registration statement must be filed within 45 days, which means this concentrated holder could start selling shares to the public soon. Any significant selling would pressure the stock, which is already trading near its 52-week low and down 48.64% over the past year.

The bottom line is binary. If the SEC clears the resale registration and the stock holds, it could be a short squeeze play. But if the registration process is delayed or the concentrated holder dumps shares, the stock could get crushed. This isn't a fundamental investment; it's a bet on a regulatory filing and a single investor's patience. Watch the filing date like a hawk.